Band 8+: WRITING TASK 2 You should spend about 40 minutes on this task. Write about the following topic: Many people in poor countries die from diseases that are curable because they cannot afford the medication required. Do you believe that drug companies should make their products available at reduced prices in these countries? Give reasons for your answer and include any relevant examples from your own knowledge and experience. Write at least 250 words.

In a world where medical advancements have reached unprecedented heights, it is a stark reality that many people in poor countries die from diseases that are curable, simply because they lack the financial means to afford necessary medications. This essay argues that pharmaceutical companies have a moral obligation to provide their products at reduced prices in these nations, highlighting the ethical implications of accessibility and the potential global benefits of such initiatives.

The moral imperative for drug companies to reduce prices in impoverished regions cannot be overstated. Many people in poor countries die from diseases that are preventable or treatable with medications that are often priced well beyond their reach. This creates a chasm of inequality in global health care, underscoring a dire need for a compassionate approach to pharmaceutical distribution. For instance, the provision of antiretroviral drugs at lowered costs in Sub-Saharan Africa has shown significant progress in the fight against HIV/AIDS, demonstrating the potential impact of affordable medication on public health.

Moreover, the argument for reducing drug prices extends beyond ethical considerations to practical benefits. By making medications more accessible in developing countries, pharmaceutical companies can play a pivotal role in curbing the spread of infectious diseases, which know no borders in our interconnected world. Additionally, healthier populations contribute to more stable and economically productive societies, which can lead to increased markets for these companies in the long term. This win-win scenario illustrates the symbiosis between corporate responsibility and business acumen.

In conclusion, the provision of medications at reduced prices in poor countries is not merely an act of charity but a necessary step towards a more equitable world. The moral and practical arguments for such measures are compelling, underscoring the urgent need for pharmaceutical companies to reconsider their pricing strategies. By doing so, they can save lives, foster global health security, and contribute to the development of thriving communities worldwide.